USX:ELDN - Eledon Pharmaceuticals, Inc Eledon Pharmaceuticals, Inc
Sector: Health Care, Industry: Biotechnology
Next Earnings: 15 Nov 2021
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 6.67    +0.180 (+2.77%)
Show Technical Chart | 1M    3M    6M    1Y    3Y    5Y         

2 Aug 2021


Loading...
Loading...
Loading...

General

CEO: Dr. David-Alexander C. Gros

IPO: 2014-09-17

Headquarters: US

Employees: 10

Homepage

Description

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.